CN110522798A - A kind of compound preparation and preparation method thereof curing mainly coronary heart disease - Google Patents
A kind of compound preparation and preparation method thereof curing mainly coronary heart disease Download PDFInfo
- Publication number
- CN110522798A CN110522798A CN201910906978.7A CN201910906978A CN110522798A CN 110522798 A CN110522798 A CN 110522798A CN 201910906978 A CN201910906978 A CN 201910906978A CN 110522798 A CN110522798 A CN 110522798A
- Authority
- CN
- China
- Prior art keywords
- parts
- heart disease
- coronary heart
- preparation
- compound preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Abstract
The present invention is suitable for field of medicaments, provide a kind of compound preparation and preparation method thereof for curing mainly coronary heart disease, according to parts by weight, the compound preparation of the treatment coronary heart disease includes following component: 7 ~ 19 parts of motherwort, 6 ~ 15 parts of Leaves of Hippophae L, 3 ~ 13 parts of Rhizoma Chuanxiong, 4 ~ 16 parts of Hyssopus officinalis, new tower spend 10 ~ 20 parts and 8 ~ 17 parts of radix paeoniae rubra.This compound preparation, pass through the rational proportion and synergistic effect between motherwort, Leaves of Hippophae L, Rhizoma Chuanxiong, Hyssopus officinalis, new tower flower and radix paeoniae rubra, has the function of the raw new, relieving restlessness and restlessness of blood circulation and channel invigorating, stasis eliminatings, cure mainly " hada A Lege " illness, show as the diseases such as precordial pain, palpitaition, uncomfortable in chest, shortness of breath, it is significant in efficacy, any toxic side effect is not found, it is highly-safe.
Description
Technical field
The invention belongs to field of medicaments more particularly to a kind of compound preparations and preparation method thereof for curing mainly coronary heart disease.
Background technique
Coronary atherosclerotic heart disease is that coronary artery occurs atherosclerotic lesion and causes blood vessel
Chamber stenosis or occlusion causes heart disease, commonly referred to as " coronary heart disease " caused by myocardial ischemia, anoxic or necrosis.According to statistics,
The illness rate city of coronary heart disease is 1.59%, and rural area 0.48% adds up to 0.77%, in rising trend.Coronary heart disease is in the U.S.
First of the cause of death is come with many developed countries.
As the limitation of Western medicine is gradually recognized and the change of world's spectrum of disease and medical model, advocate natural
Drug is just becoming a kind of worldwide trend, and Chinese Medicine Industry is faced with unprecedented opportunities.But due to modernization of Chinese medicine
The reasons such as modernization level is low, the generally existing production technology backwardness of Chinese Medicine Industry, unstable product quality, scientific and technological content are low etc.
Problems cause the competitiveness in the international market of Chinese Medicine Industry weak, and Chinese Medicine Industry is faced with stern challenge.
And at present in the Chinese patent drugs of numerous treatment coronary heart disease, the effect of various effective ingredient in Chinese respectively give priority to not
Together, clinically there is the great demand of drug combination.Therefore it provides the clinical illness specific aim that adapts to is stronger, safely and effectively control
Treating coronary heart disease compound preparation has important clinical meaning.
Treating coronary disease with traditional Chinese medicine, the ethnic drug research and development especially with unique treatment special advantage have caused medical work
Author greatly pays close attention to, and, mainly based on diagnosis and treatment based on an overall analysis of the illness and the patient's condition, treating both manifestation and root cause of disease makes patients with coronary artery disease fundamentally obtain rehabilitation, now for it
The ethnic drug that domestic external application is used to treat coronary heart disease is constantly in blank conceptual phase, therefore the people of developmental research treatment coronary heart disease
Race's Chinese medicine has good market prospects.
Summary of the invention
The embodiment of the present invention provides a kind of compound preparation for curing mainly coronary heart disease, it is intended to which solution provides a kind of clinical adaptation illness
Specific aim is stronger, safely and effectively treats coronary heart disease compound preparation.
The embodiments of the present invention are implemented as follows, a kind of compound preparation curing mainly coronary heart disease, according to parts by weight, including such as
Lower component: 7~19 parts of motherwort, 6~15 parts of Leaves of Hippophae L, 3~13 parts of Rhizoma Chuanxiong, 4~16 parts of Hyssopus officinalis, new tower spend 10~20 parts and
8~17 parts of radix paeoniae rubra.
The embodiment of the invention also provides a kind of preparation methods of compound preparation for curing mainly coronary heart disease, include the following steps:
Each component is weighed according to the formula of the above-mentioned compound preparation for curing mainly coronary heart disease, it is spare；By motherwort, Leaves of Hippophae L, Rhizoma Chuanxiong,
Hyssopus officinalis, new tower flower and radix paeoniae rubra crush after being separately dried, and cross 50~120 meshes, obtain being pulverized and mixed material；Described crush is mixed
It closes material to be put into container, 4~8 times of amount water of material quantity is added, decoct 2~2.5 hours, filtration obtains aqueous extract and filter
Slag；Ultrafiltration is carried out to the aqueous extract, the extracting solution after obtaining ultrafiltration；It is molten that its 5~6 times ethyl alcohol is added into the filter residue
Liquid carries out refluxing extraction 1~2 time, merges refluxing extraction filtrate, obtains alcohol extract；By after the ultrafiltration extracting solution and alcohol extracting
Liquid is taken to merge, part is concentrated under reduced pressure into the concentration thick paste that relative density is 1.25~1.36；The concentrated extract is heated to
It 50~65 DEG C, material 25~30 minutes, moves to temperature and is maintained in 85 DEG C or more of drop tank；Medical fluid is dropped to 6~8 DEG C of methyl
In silicone oil, take out dripping pill, be fitted into after oil removing in capsule to get.
The compound preparation provided in an embodiment of the present invention for curing mainly coronary heart disease, by motherwort, Leaves of Hippophae L, Rhizoma Chuanxiong, Hyssopus officinalis,
Rational proportion and synergistic effect between new tower flower and radix paeoniae rubra have the function of the raw new, relieving restlessness and restlessness of blood circulation and channel invigorating, stasis eliminatings, and
It is significant in efficacy, it has no toxic side effect, it is highly-safe.
Specific embodiment
In order to make the objectives, technical solutions, and advantages of the present invention clearer, below in conjunction with specific embodiment, to this
Invention is further elaborated.It should be appreciated that the specific embodiments described herein are merely illustrative of the present invention, not
For limiting the present invention.
The compound preparation provided in an embodiment of the present invention for curing mainly coronary heart disease, by motherwort, Leaves of Hippophae L, Rhizoma Chuanxiong, Hyssopus officinalis,
Rational proportion and synergistic effect between new tower flower and radix paeoniae rubra have the function of the raw new, relieving restlessness and restlessness of blood circulation and channel invigorating, stasis eliminatings, and
It is significant in efficacy, it has no toxic side effect, it is highly-safe.
The embodiment of the invention provides a kind of compound preparations for curing mainly coronary heart disease, according to parts by weight, including following component:
7~19 parts of motherwort, 6~15 parts of Leaves of Hippophae L, 3~13 parts of Rhizoma Chuanxiong, 4~16 parts of Hyssopus officinalis, new tower spend 10~20 parts and radix paeoniae rubra 8~
17 parts.
Including following component preferably, according to parts by weight: 10~19 parts of motherwort, 8~13 parts of Leaves of Hippophae L, Rhizoma Chuanxiong 3~
10 parts, 4~15 parts of Hyssopus officinalis, new tower spend 10~15 parts and 10~17 parts of radix paeoniae rubra.
More preferably, according to parts by weight, including following component: 12 parts of motherwort, 12 parts of Leaves of Hippophae L, 9 parts of Rhizoma Chuanxiong, mind
10 parts of vanilla, new tower spend 12 parts and 12 parts of radix paeoniae rubra.
The ingredient and effect of raw material used in the embodiment of the present invention are described in detail below.
Motherwort: for the fresh or dry aerial parts of Labiatae mother wort plant, acrid flavour, slight bitter, cold nature enters the heart
Packet, Liver Channel have the effect of stasis of blood, inducing diuresis to remove edema are adjusted in promoting blood circulation.It is used clinically for irregular menstruation, postpartum stasis caused pain, cardiovascular and cerebrovascular disease
The treatment of the diseases such as disease, blood disease.
Motherwort herb contains alkaloid 0.11%~2.09%, wherein leonurine 0.02%~0.12%, stachydrine
0.59%~1.72% and motherwort pyridine, leonurinine.Motherwort also contains flavones ingredient: apiolin, overgrown with weeds florigen and its glycosides, Mongolian oak
Pi Su, Kaempferide and its glycosides, rutin, 5,7,3,4,5 ,-pentamethoxyl flavones, wogonin, daidzein.Reported benefit is female
Grass, which belongs to Diterpenoids from bulbus, more than 10, and in addition to a kind of Wei Cheng paulownia alkane type, other are half-day type bicyclic diterpene, preceding Spain
Summer sieve humulone, Spain's summer sieve humulone (motherwort element), preceding motherwort B prime, Persian motherwort element A, B, leoheteronin
(new Ladanum alkane diterpene in motherwort) A, B, C, D, E.
Pharmacological activity: motherwort can improve haemodynamics and hemorheology, to platelet aggregation, thrombosis with
And erythrocyte aggregation has inhibiting effect.Motherwort total alkaloid has apparent anti-inflammatory and analgesic effect, can improve myocardial ischemia,
Increase coronary flow, improve heart function, mechanism passes through scavenging activated oxygen, inhibition mainly under oxidative stress status
Reactive oxygen species, which generate, plays antioxidation, and another mechanism of motherwort cardioprotection is to promote angiogenesis.
Leaves of Hippophae L: also known as vinegar willow, it is Elaeangnaceae shrub or dungarunga, originates in Asia and Europe, South and North America widely plant
Training.China's sea buckthorn resources are abundant, there are four five subspecies are planted, are mainly distributed on a province in northwest, North China, northeast and southwest etc. more than ten
Area.Sea-buckthorn is the function plant of dietotherapeutic, in China by extensive with for Tibetan medicine, anaesthetic, Kazakhstan medicine and Chinese medicine, beginning quilt in 1997
" Chinese Pharmacopoeia " records.
Leaves of Hippophae L contains nutritional ingredient extremely abundant and physiological activator as fructus hippophae, mainly have protein,
Polysaccharide, organic acid, alkaloid, flavonoids, amino acid, carotenoid, chlorophyll and microelement etc..Contain in Leaves of Hippophae L
The flavonoid glycoside of the compositions such as more flavone compound, mainly Isorhamnetin, Quercetin and Kaempferol, myricetin constitutes glucoside
The sugar of class has glucose, rhamnose, arabinose and galactolipin, and occurs mostly in the form of 3-O- glucoside, and the content in leaf
Higher than the content in fruit.The compounds such as ursolic acid, oleanolic acid, sitosterol, stigmasterol, amyrin are isolated from Leaves of Hippophae L.From
L4 kind triterpene compounds are measured in Leaves of Hippophae L dichlorodifluoromethan medicinal extract, including ring vitellin alcohol (2.7%), cholesterol
(0.4%), 2,4- ethyl cholesteric -7- ring-β -ol (1.5%), Gao Ergen alcohol (2.7%), the unsaturation such as lupeol alcohols are put down
Angle steroid enol, α-amyrin, β-amyrin, cupreol, astragalin and rubber alcohol etc..
Pharmacological activity: sea-buckthorn leaf extract has TC, TG in the exogenous experimental rat serum high in fat of reduction, increases exogenous
The effect of HDL-C/TC, can be used for preventing and treating hyperlipidemia in experimental rat serum high in fat.Total Flavone in Hippopae has
Increase coronary blood flow, reduce myocardial oxygen consumption, inhibits platelet aggregation, can significantly reduce whole blood contrast viscosity, can be used for
The treatment of cardiovascular and cerebrovascular diseases.
Rhizoma Chuanxiong: it is acrid flavour, slight bitter, warm-natured for the dry rhizome of umbelliferae Rhizoma Chuanxiong, have promoting blood circulation dispel disease, promote breath and open depression,
The effect of wind-expelling pain-stopping.Clinically it is mainly used for treating cardiovascular disease, gynecological disease etc..
Rhizoma Chuanxiong mainly contains alkaloid, phthalide-type and organic acid substance.Contained phthalide substance has ligustilide, Rhizoma Chuanxiong
Phenol, 5- hydroxyl -3- butylidenephthalide, 3- butylphthalide, 3- butylidenephthalide, 7- hydroxyl -3- butylidenephthalide, in new cnidium monnieri
Ester, trans- 6,7- dihydroxy Ligustilide, cis- 6,7- dihydroxy Ligustilide.Alkaloid in Rhizoma Chuanxiong has ligustrazine, 1- (5- hydroxyl
Methyl -2- furyl) β-card quinoline, 1- β-ethyl acrylate -7- aldehyde radical-β-card quinoline, 1- acetyl group-β-card quinoline.Having in Rhizoma Chuanxiong
Machine acid has ferulic acid, caffeic acid, vanillic acid, protocatechuic acid, sedanoic acid.
Pharmacological activity: effective component ligustrazine, vanillic aldehyde and big flavones in Rhizoma Chuanxiong may act on myocardial cell membrane by
Body, wherein ligustrazine is possible to act on α receptor, and vanillic aldehyde is possible to act on β1receptor.Ligustrazine can make myocardial contractive power
Enhancing has preferable protective effect to treating myocardial ischemia damage.Ligustrazine, which has, inhibits vasoconstrictive effect, can expand coronal
Artery, the cerebrovascular, Pulmonary Vascular, Renal vascular and peripheral vessels.Ligustrazine can be such that intracellular cAMP levels increase, and be by cAMP etc.
The mediation of system influences the non-Ca of vascular smooth muscle2+It removes, reduces intracellular Ca2+Concentration, so as to cause relaxing the VSM.River
Rhizome of chuanxiong all has protective effect to cerebral ischemia, Ischemic-reperfused and cerebral infarction injury.Ferulic acid in Rhizoma Chuanxiong is for cranial nerve
It is ready with protective effect.
Hyssopus officinalis: for the herb of Lamiaceae plant, whole plant for medical use, complete stool mainly contains volatile oil, is usually used in antitussive and antiasthmatic, clearly
Hot dampness removing.
Hyssopus officinalis is fragrant plant, and chemical constitution study is concentrated mainly on volatile oil, volatile oil main component be it is inner that
Alcohol 49%, eucalyptol 14.9%, limonene 5% are other also to contain isopinocamphone He limonene etc..From the firmly sharp Hyssopus officinalis of congener
In isolated 7 compounds, be identified respectively as Chrysin, 20 tetramethylene cycloartanols, oleanolic acid, hexadecane
Alcohol, ceryl alcohol, cupreol, daucosterol.
Recent study discovery, Hyssopus officinalis have the bioactivity such as anti-asthma, spasmolysis, hypoglycemic, antibacterial, cough-relieving, anti-aging.
New tower flower: having effects that heart tonifying dampness removing, regulating qi-flowing for eliminating phlegm, diminishing inflammation and resolving masses, for treat heart disease, shortness of breath hidrosis,
The illness such as oedema, cough, tracheitis, pulmonary abscess.
Fragrant new tower flower mainly contains the ingredients such as flavones, organic acid, triterpene, sterol and volatile oil.Current separated identification
Flavones ingredient have acacetin, apiolin, chrysoeriol, kaempferol, Hyperoside, Quercetin, Quercetin 3-O-B-D-
Glucopyranoside, 5,6,4- trihydroxies -7,8,3- trimethoxy flavone；Organic acid have oleanolic acid, salicylic acid, caffeic acid,
Methyl rosmarinate, Rosmarinic acid, 3- (3,4- dihydroxy phenyl)-methyl lactate, protocatechuic acid；Other compounds have galactolipin
Alcohol, B- sitosterol, daucosterol, hitodesterol, hitodesterol -3-O-B-D- glucopyranoside.During fragrant new tower is spent
Volatile oil main component is bicyclic [the 4,4,0] -1- alkene (11.59%) of 2- isopropyl -5- methyl -9- methylene, C- elemene
(8.53%), 1- fluomethane -3- nitrobenzol (7.57%), australene (4.18%) etc..
Fragrant new tower flower has anti-inflammatory and analgesic effect, and the new tower flower flavones of fragrance has antioxidant activity and to the rat suckling mouse heart
Myocyte's anoxia/reoxygenation has significant protective effect, and mechanism may expand blood vessel, suppression with fragrant Folium Billbergiae extract
Oxygen radical processed is related to the damage of cardiac muscle.
Radix paeoniae rubra: for ranunculaceae plant Chinese herbaceous peony or the dry root of the dry root of river radix paeoniae rubra, bitter, cold nature, return liver warp.Function
The analgesic of the row stasis of blood, cool blood detumescence；Cure mainly the stagnant menostasis of the stasis of blood, the accumulation of hernia lump in the abdomen, abdominal pain hypochondriac pain, bleeding from five sense organs or subcutaneous tissue bloody flux, discharging fresh blood stool, hot eyes carbuncle swells.
Modern pharmacological studies have shown that radix paeoniae rubra have a variety of pharmacological functions, mainly act on cardiovascular system, in addition also have it is antitumor,
Antiendotoxin etc..
Radix paeoniae rubra has stronger antioxidant activity, the study found that the ethanol extract gallic acid of radix paeoniae rubra, gallic acid first
Ester can remove DPPH free radical, and to Anti-lipid peroxidation, also can inhibit the NIH/3T3 of hydrogen peroxide-induced into fiber finer
The DNA damage of born of the same parents, 50% ethanol extract of radix paeoniae rubra can inhibit in peripheral blood in mice by KBrO3The micronucleus desmacyte of induction
It is formed.In addition, research discovery radix paeoniae rubra can induce the expression of Protoheme oxygendase-1, the activity of SOD, anti-lipid peroxidation are improved
Reaction has protective effect to lungs.
The embodiment of the invention also provides a kind of preparation methods of compound preparation for curing mainly coronary heart disease, include the following steps:
Each component is weighed according to the formula of the above-mentioned compound preparation for curing mainly coronary heart disease, it is spare.
It is crushed after motherwort, Leaves of Hippophae L, Rhizoma Chuanxiong, Hyssopus officinalis, new tower flower and radix paeoniae rubra are separately dried, crosses 50~120 meshes,
It obtains being pulverized and mixed material.
The material that is pulverized and mixed is put into container, 4~8 times of amount water of material quantity are added, is decocted 2~2.5 hours, filter
It crosses, obtains aqueous extract and filter residue.
Ultrafiltration is carried out to the aqueous extract, the extracting solution after obtaining ultrafiltration.
Its 5~6 times ethanol solution is added into the filter residue to carry out refluxing extraction 1~2 time, merges refluxing extraction filter
Liquid obtains alcohol extract.
By after the ultrafiltration extracting solution and alcohol extract merge, part be concentrated under reduced pressure into relative density be 1.25~
1.36 concentration thick paste.
The concentrated extract is heated to 50~65 DEG C, material 25~30 minutes, temperature is moved to and is maintained at 85 DEG C or more
It drips in tank.
Medical fluid is dropped in 6~8 DEG C of methyl-silicone oil, take out dripping pill, be fitted into after oil removing in capsule to get.
In embodiments of the present invention, above-mentioned that the material that is pulverized and mixed is put into container, 4~8 times that material quantity is added
The step of measuring water, decocting 2~2.5 hours, filter, obtain aqueous extract and filter residue, comprising: be put into the material that is pulverized and mixed
In container, 6 times of amount water of material quantity are added, decoct 2.5 hours, filtration obtains aqueous extract and filter residue.
In embodiments of the present invention, above-mentioned that ultrafiltration carried out to the aqueous extract, the step of extracting solution after obtaining ultrafiltration,
It include: to carry out ultrafiltration with the filter membrane that molecule interception is 50000, filter type uses cross-flow filtration.The operation of the ultrafiltration
Condition are as follows: inlet pressure be 0.15~0.3MPa, the low 0.1MPa of liquid outlet pressure ratio inlet pressure, feed velocity be 4~
5m/s is intermittently passed through nitrogen during ultra-filtration, forms gas-liquid stream of pulses, ventilation in every 1~1.5 hour is primary, every time ventilation 2~3
Minute.
In embodiments of the present invention, described that ultrafiltration carried out to the aqueous extract, the step of extracting solution after obtaining ultrafiltration,
Include: to keep the temperature of the aqueous extract at 45~55 DEG C, carries out ultrafiltration, the extracting solution after obtaining ultrafiltration.
In embodiments of the present invention, described its 5~6 times ethanol solution that is added into the filter residue carries out refluxing extraction 1
~2 times, merge refluxing extraction filtrate, the step of obtaining alcohol extract, comprising: be added in Xiang Suoshu filter residue its 5 times 60%
Ethanol solution carries out first refluxing extraction 1.5 hours, and after filtration, 75% ethanol solution that 5 times of amounts are added is carried out second time
Stream extracts 2 hours, merges the filtrate of refluxing extraction twice, obtains alcohol extract.
In embodiments of the present invention, described that the concentrated extract is heated to 50~65 DEG C, it material 25~30 minutes, moves to
Temperature is maintained at the step in 85 DEG C or more of drop tank, comprising: the concentrated extract is heated to 50 DEG C, material 30 minutes, is moved
In the drop tank for being maintained at 85 DEG C or more to temperature.
The compound preparation provided in an embodiment of the present invention for curing mainly coronary heart disease is produced to clinical preparation effective, that market prospects are good
The full crushing of former grass, extraction are prepared decoction technique and are changed to extract entirely, and separated, purify, prepare plastic by the secondary development that product carry out
Capsule meets the requirement of the modernization of Chinese medicine to improve its scientific and technological content and added value.Using the compound system of modern technology development
Agent is better than prior art in terms of blood circulation and channel invigorating, raw new, the relieving restlessness and restlessness function curative effect of stasis eliminatings, can be used for controlling after process optimization
" hada A Lege " illness is treated, the diseases such as precordial pain, palpitaition, uncomfortable in chest, shortness of breath, more remarkable treatment effect are shown as.
Below by way of technical effect of the specific embodiment to the compound preparation for curing mainly coronary heart disease of the embodiment of the present invention do into
The explanation of one step.
Embodiment 1,
The compound preparation for curing mainly coronary heart disease of the embodiment of the present invention is prepared by following step:
By following formulas, to weigh each raw material spare: 10 parts of motherwort, 6 parts of Leaves of Hippophae L, 10 parts of Rhizoma Chuanxiong, 16 parts of Hyssopus officinalis,
New tower spends 15 parts and 10 parts of radix paeoniae rubra.
It is crushed after motherwort, Leaves of Hippophae L, Rhizoma Chuanxiong, Hyssopus officinalis, new tower flower and radix paeoniae rubra are separately dried, crosses 50 meshes, obtain
It is pulverized and mixed material.The material that is pulverized and mixed is put into container, 6 times of amount water of material quantity are added, is decocted 2.5 hours, filter
It crosses, obtains aqueous extract and filter residue.Ultrafiltration is carried out with the filter membrane that molecule interception is 50000, keeps the aqueous extract
For temperature at 55 DEG C, filter type uses cross-flow filtration, the operating condition of ultrafiltration are as follows: inlet pressure is 0.15MPa, liquid outlet pressure
Power is 0.1MPa lower than inlet pressure, feed velocity 5m/s, is intermittently passed through nitrogen during ultra-filtration, forms gas-liquid stream of pulses,
Ventilation in every 1 hour is primary, every time ventilation 2 minutes；Extracting solution after obtaining ultrafiltration.Be added into the filter residue its 5 times 60%
Ethanol solution carry out first refluxing extraction 1.5 hours, after filtration, 75% ethanol solution that 5 times of amounts are added carries out second
Refluxing extraction 2 hours, merges the filtrate of refluxing extraction twice, obtain alcohol extract.By after the ultrafiltration extracting solution and alcohol extracting
Liquid is taken to merge, part is concentrated under reduced pressure into the concentration thick paste that relative density is 1.25.The concentrated extract is heated to 50 DEG C, is changed
Material 30 minutes moves to temperature and is maintained in 85 DEG C or more of drop tank.Medical fluid is dropped in 6 DEG C of methyl-silicone oil, takes out dripping pill, remove
Be fitted into after oil in capsule to get.
Embodiment 2,
The compound preparation for curing mainly coronary heart disease of the embodiment of the present invention is prepared by following step:
By following formulas, to weigh each raw material spare: 7 parts of motherwort, 15 parts of Leaves of Hippophae L, 3 parts of Rhizoma Chuanxiong, 4 parts of Hyssopus officinalis, new
Tower spends 10 parts and 8 parts of radix paeoniae rubra.
It is crushed after motherwort, Leaves of Hippophae L, Rhizoma Chuanxiong, Hyssopus officinalis, new tower flower and radix paeoniae rubra are separately dried, sieves with 100 mesh sieve, obtain
It is pulverized and mixed material.The material that is pulverized and mixed is put into container, 4 times of amount water of material quantity are added, is decocted 2.5 hours, filter
It crosses, obtains aqueous extract and filter residue.Ultrafiltration is carried out with the filter membrane that molecule interception is 50000, keeps the aqueous extract
For temperature at 45 DEG C, filter type uses cross-flow filtration, the operating condition of ultrafiltration are as follows: inlet pressure is 0.3MPa, liquid outlet pressure
Power is 0.1MPa lower than inlet pressure, feed velocity 4m/s, is intermittently passed through nitrogen during ultra-filtration, forms gas-liquid stream of pulses,
Ventilation in every 1 hour is primary, every time ventilation 3 minutes；Extracting solution after obtaining ultrafiltration.Be added into the filter residue its 5 times 60%
Ethanol solution carry out first refluxing extraction 1.5 hours, after filtration, 75% ethanol solution that 5 times of amounts are added carries out second
Refluxing extraction 2 hours, merges the filtrate of refluxing extraction twice, obtain alcohol extract.By after the ultrafiltration extracting solution and alcohol extracting
Liquid is taken to merge, part is concentrated under reduced pressure into the concentration thick paste that relative density is 1.36.The concentrated extract is heated to 65 DEG C, is changed
Material 25 minutes moves to temperature and is maintained in 85 DEG C or more of drop tank.Medical fluid is dropped in 6 DEG C of methyl-silicone oil, takes out dripping pill, remove
Be fitted into after oil in capsule to get.
Embodiment 3,
The compound preparation for curing mainly coronary heart disease of the embodiment of the present invention is prepared by following step:
By following formulas, to weigh each raw material spare: 19 parts of motherwort, 8 parts of Leaves of Hippophae L, 5 parts of Rhizoma Chuanxiong, 15 parts of Hyssopus officinalis, new
Tower spends 12 parts and 17 parts of radix paeoniae rubra.
It is crushed after motherwort, Leaves of Hippophae L, Rhizoma Chuanxiong, Hyssopus officinalis, new tower flower and radix paeoniae rubra are separately dried, crosses 120 meshes, obtain
It is pulverized and mixed material.The material that is pulverized and mixed is put into container, 8 times of amount water of material quantity are added, is decocted 2 hours, filtration,
Obtain aqueous extract and filter residue.Ultrafiltration is carried out with the filter membrane that molecule interception is 50000, keeps the temperature of the aqueous extract
At 50 DEG C, filter type uses cross-flow filtration, the operating condition of ultrafiltration are as follows: inlet pressure is 0.20MPa, liquid outlet pressure ratio
Inlet pressure low 0.1MPa, feed velocity 4.5m/s are intermittently passed through nitrogen during ultra-filtration, form gas-liquid stream of pulses, often
Ventilation in 1.5 hours is primary, every time ventilation 3 minutes；Extracting solution after obtaining ultrafiltration.Be added into the filter residue its 5 times 60%
Ethanol solution carry out first refluxing extraction 1.5 hours, after filtration, 75% ethanol solution that 5 times of amounts are added carries out second
Refluxing extraction 2 hours, merges the filtrate of refluxing extraction twice, obtain alcohol extract.By after the ultrafiltration extracting solution and alcohol extracting
Liquid is taken to merge, part is concentrated under reduced pressure into the concentration thick paste that relative density is 1.30.The concentrated extract is heated to 50 DEG C, is changed
Material 30 minutes moves to temperature and is maintained in 85 DEG C or more of drop tank.Medical fluid is dropped in 6 DEG C of methyl-silicone oil, takes out dripping pill, remove
Be fitted into after oil in capsule to get.
Embodiment 4,
The compound preparation for curing mainly coronary heart disease of the embodiment of the present invention is prepared by following step:
By following formulas, to weigh each raw material spare: 12 parts of motherwort, 12 parts of Leaves of Hippophae L, 9 parts of Rhizoma Chuanxiong, 10 parts of Hyssopus officinalis,
New tower spends 12 parts and 12 parts of radix paeoniae rubra.
It is crushed after motherwort, Leaves of Hippophae L, Rhizoma Chuanxiong, Hyssopus officinalis, new tower flower and radix paeoniae rubra are separately dried, crosses 80 meshes, obtain
It is pulverized and mixed material.The material that is pulverized and mixed is put into container, 5 times of amount water of material quantity are added, is decocted 2.5 hours, filter
It crosses, obtains aqueous extract and filter residue.Ultrafiltration is carried out with the filter membrane that molecule interception is 50000, keeps the aqueous extract
For temperature at 45 DEG C, filter type uses cross-flow filtration, the operating condition of ultrafiltration are as follows: inlet pressure is 0.15MPa, liquid outlet pressure
Power is 0.1MPa lower than inlet pressure, feed velocity 4m/s, is intermittently passed through nitrogen during ultra-filtration, forms gas-liquid stream of pulses,
Ventilation in every 1.5 hours is primary, every time ventilation 2 minutes；Extracting solution after obtaining ultrafiltration.Its 5 times are added into the filter residue
60% ethanol solution carries out first refluxing extraction 1.5 hours, and after filtration, 75% ethanol solution that 5 times of amounts are added carries out the
Secondary back extracts 2 hours, merges the filtrate of refluxing extraction twice, obtains alcohol extract.By after the ultrafiltration extracting solution and
Alcohol extract merges, and part is concentrated under reduced pressure into the concentration thick paste that relative density is 1.25.The concentrated extract is heated to 50
DEG C, it material 30 minutes, moves to temperature and is maintained in 85 DEG C or more of drop tank.Medical fluid is dropped in 8 DEG C of methyl-silicone oil, takes out drop
Ball, be fitted into after oil removing in capsule to get.
Embodiment 5,
The compound preparation for curing mainly coronary heart disease of the embodiment of the present invention is prepared by following step:
By following formulas, to weigh each raw material spare: 15 parts of motherwort, 10 parts of Leaves of Hippophae L, 13 parts of Rhizoma Chuanxiong, 8 parts of Hyssopus officinalis,
New tower spends 20 parts and 15 parts of radix paeoniae rubra.
It is crushed after motherwort, Leaves of Hippophae L, Rhizoma Chuanxiong, Hyssopus officinalis, new tower flower and radix paeoniae rubra are separately dried, sieves with 100 mesh sieve, obtain
It is pulverized and mixed material.The material that is pulverized and mixed is put into container, 5 times of amount water of material quantity are added, is decocted 2.5 hours, filter
It crosses, obtains aqueous extract and filter residue.Ultrafiltration is carried out with the filter membrane that molecule interception is 50000, keeps the aqueous extract
For temperature at 45 DEG C, filter type uses cross-flow filtration, the operating condition of ultrafiltration are as follows: inlet pressure is 0.20MPa, liquid outlet pressure
Power is 0.1MPa lower than inlet pressure, feed velocity 5m/s, is intermittently passed through nitrogen during ultra-filtration, forms gas-liquid stream of pulses,
Ventilation in every 1 hour is primary, every time ventilation 3 minutes；Extracting solution after obtaining ultrafiltration.Be added into the filter residue its 5 times 60%
Ethanol solution carry out first refluxing extraction 1.5 hours, after filtration, 75% ethanol solution that 5 times of amounts are added carries out second
Refluxing extraction 2 hours, merges the filtrate of refluxing extraction twice, obtain alcohol extract.By after the ultrafiltration extracting solution and alcohol extracting
Liquid is taken to merge, part is concentrated under reduced pressure into the contracting thick paste that relative density is 1.36.The concentrated extract is heated to 65 DEG C, material
It 30 minutes, moves to temperature and is maintained in 85 DEG C or more of drop tank.Medical fluid is dropped in 7 DEG C of methyl-silicone oil, takes out dripping pill, oil removing
Be fitted into capsule afterwards to get.
Comparative example 1,
The compound preparation for curing mainly coronary heart disease of the comparative example is prepared by following step:
By following formulas, to weigh each raw material spare: 12 parts of motherwort, 12 parts of Leaves of Hippophae L, 9 parts of Rhizoma Chuanxiong, 10 parts of Hyssopus officinalis,
New tower spends 12 parts and 12 parts of radix paeoniae rubra.
It is crushed after motherwort, Leaves of Hippophae L, Rhizoma Chuanxiong, Hyssopus officinalis, new tower flower and radix paeoniae rubra are separately dried, crosses 80 meshes, obtain
It is pulverized and mixed material.The material that is pulverized and mixed is put into container, 5 times of amount water of material quantity are added, is decocted 2.5 hours, filter
It crosses, obtains aqueous extract and filter residue.Its 5 times 60% ethanol solution is added into the filter residue and carries out first refluxing extraction
1.5 hours, after filtration, 75% ethanol solution that 5 times of amounts are added was carried out second refluxing extraction 2 hours, and merging flows back twice
The filtrate of extraction, obtains alcohol extract.The aqueous extract and alcohol extract are merged, part is concentrated under reduced pressure into relative density
For 1.25 concentration thick paste.The concentrated extract is heated to 50 DEG C, material 30 minutes, temperature is moved to and is maintained at 85 DEG C or more
It drips in tank.Medical fluid is dropped in 8 DEG C of methyl-silicone oil, take out dripping pill, be fitted into after oil removing in capsule to get.
The comparative example and the difference of above-described embodiment 4 are only that, the step of carrying out ultrafiltration to aqueous extract is omitted.
The compound preparation that coronary heart disease is cured mainly to provided in an embodiment of the present invention carry out following experiment verify its safety with
And curative effect.
(1) acute oral toxicity test
1, test method:
The appearance that 25 grams of the compound preparation product for curing mainly coronary heart disease for taking the offer of the embodiment of the present invention 1~5 respectively are 1~5 to number
In measuring bottle, ultrapure water is added and is settled to 100mL, mixes and is used as experimental liquid.
Trial test: oral stomach-filling test is carried out to experimental animal using the experimental liquid of 5000mg/kg body weight dose, is not found
There is death in experimental animal, therefore formal test design dosage is 5000mg/kg weight.
Formal test: choosing 60 healthy, 18~20 grams of weight SPF grade kunming mices, and stochastic averagina is divided into 6 groups,
Every group each 10, half male and half female, and numbering is 1~6, wherein group 1 is blank control group, is filled by the amount of 0.2mL/10g weight
Pure water is given in oral 1 stomach-filling of stomach needle；Oral 1 stomach-filling of amount gastric perfusion needle of 0.2mL/10g weight is pressed respectively in group 2~groups 6
1~No. 5 experimental liquid is given, that is, organizes 2 and gives No. 1 experimental liquid, group 3 gives No. 2 experimental liquids, and group 4 gives No. 3 experimental liquids, and group 5 is given
No. 4 experimental liquids, group 6 give No. 5 experimental liquids.Groups of animals fasting 16 hours before stomach-filling, free water give normal drink after stomach-filling
Food, the Routine Management under conditions of 22 ± 1 DEG C of room temperature, humidity 60 ± 5%；Identical number of days is raised, is observed in mouse daily
Toxication shape and death condition after the completion of test in 14 days, carry out data statistics to test result.
Wherein, it during this test, is poisoned during finger to finger test, mouse occurs trembling, twitch, salivate, diarrhea, drowsiness
With stupor etc. symptoms.Oral toxicity classification is as shown in table 1 below:
Table 1
| LD50(mg/Kg) | ≤50 | 51~500 | 501~5000 > 5000 |
| Toxicity grading | High poison | Medium poison | It is less toxic practical nontoxic |
During the whole test process, the diet activity of each group animal subject normally has no obvious poisoning symptom and death.Thus may be used
See, the mouse oral toxicity LD for the treatment of coronary heart disease provided in an embodiment of the present invention50> 5000mg/kg weight, safety are good.
(2) the influence test to mouse oxygen deficit tolerance takes healthy male mice 130,18~22g of weight, and random point
At 13 groups, every group 10, respectively blank control group, example 1 group, 3 groups of embodiment, 4 groups of embodiment, are implemented 2 groups of embodiment
5 groups of example, 1 group of comparative example, motherwort control group, Leaves of Hippophae L control group, Rhizoma Chuanxiong control group, Hyssopus officinalis control group, new tower flower control
Group and radix paeoniae rubra control group.Each group administration group mouse presses 0.5mL/20g weight gastric infusion, and blank control group gives the super of same volume
Pure water is administered once a day, and after successive administration 10 days, last time administration 30 minutes, mouse merging is equipped with 10g sodium stone respectively
In the 250mL wide-mouth sand plug bottle of ash, bottleneck is sealed, death time of animal is observed, as a result see the table below 2.
Influence (± s) of 2 test sample of table to the death time in mouse normal pressure anoxia tolerance test
Note: the * p < 0.05 compared with blank control group；* p < 0.01；* * p < 0.001.
Each embodiment group, one pack system control group and comparative example group and blank control it can be seen from the test result of upper table 2
Group compares, and can significantly improve the hypoxia-bearing capability of mouse, extend its death time, wherein embodiment group and blank control
Group compares, and has significant difference (p < 0.05 or p < 0.01), and embodiment group extends it to the hypoxia-bearing capability for improving mouse
The effect of death time is especially prominent compared with the effect of one pack system control group and comparative example group.
(3) cause the influence of Rat Experimental myocardial ischemia to be tested pituitrin and take healthy SD rat 130, it is female
Fifty-fifty, the 18~22g of weight of hero, is randomly divided into 13 groups, every group 10, respectively blank control group, example 1 group, embodiment 2
Group, 3 groups of embodiment, 4 groups of embodiment, 5 groups of embodiment, 1 group of comparative example, motherwort control group, Leaves of Hippophae L control group, Rhizoma Chuanxiong control
Group, Hyssopus officinalis control group, new tower flower control group and radix paeoniae rubra control group.It is 4g raw that test specimen, which is configured to concentration with pure water,
Medicine/kg weight, every group of animal press 1mL/100g weight gastric infusion, and blank control group is given isometric pure water, given daily
Medicine is primary, and successive administration 10 days.30 minutes after last time administration, intraperitoneal injection yellow Jackets (40mg/kg weight) anesthesia
Animal, and 1 hour after gastric infusion, rat tail vein injection of pituitrin (1u/kg), after observing and recording injection hypophysis
Foline is 30 seconds forward and backward, 1min, 2min, 3min, 4min and 5min two lead electrocardiogram (ECG), with T wave it is low it is flat, two-way, fall
It sets, ST sections of levels move down, and heart murmur, the index that decreased heart rate is treating myocardial ischemia damage are compared to ECG before and after pituitrin
Change and carries out administration group compared with blank control group.
Test result shows that embodiment group and the test sample of one pack system control group and comparative example group draw pituitrin
The Rat Experimental myocardial ischemia risen has some improvement, wherein embodiment group has conspicuousness compared with blank control group
Difference (p < 0.05), and the improvement of embodiment group is more preferable compared with the effect of one pack system control group and comparative example group.
(4) clinical test selection is diagnosed as 120 progress clinical observations of inpatient of coronary disease and angina pectoris, Bing Rensui
Machine is divided into 6 groups, every group 20, respectively control group, example 1 group, 2 groups of embodiment, 3 groups of embodiment, 4 groups of embodiment and implementation
5 groups of example.The course of disease 1~3 year, the age 38~65 years old, wherein angina pectoris 21, myocardial ischemia 50, heart neurosis
20, chronic bronchitis 29.To the case strict control variable factor for being included in this test.
When test, the case of control group takes Xinshubao Capsule, 2 times a day, 2 tablets each time, 15 days as a treatment course.Implement
The case that 1 group of example takes the compound preparation of the treatment coronary heart disease of the offer of the embodiment of the present invention 1, and the case that 2 groups of embodiment takes this
The compound preparation for the treatment coronary heart disease that inventive embodiments 2 provide, the case that 3 groups of embodiment take the offer of the embodiment of the present invention 3
The compound preparation of coronary heart disease is treated, the case that 4 groups of embodiment takes the compound system of the treatment coronary heart disease of the offer of the embodiment of the present invention 4
Agent, the case that 5 groups of embodiment take the compound preparation of the treatment coronary heart disease of the offer of the embodiment of the present invention 5.The disease of each embodiment group
Example takes orally the dosage of 180mg, 2 times a day, 15 days as a treatment course every time.Test result see the table below 3.
Curative effect judging standard: it cures: symptom disappear or mostly disappear.Effective: above-mentioned symptom is relieved.It is invalid: disease
Shape is not improved.
Table 3
It can be seen that the cure rate of embodiment group from the test result of upper table 3 and total effective rate be apparently higher than control group.As it can be seen that
The compound preparation provided in an embodiment of the present invention for curing mainly coronary heart disease can be used for treating coronary heart disease.
The compound preparation provided in an embodiment of the present invention for curing mainly coronary heart disease, by motherwort, Leaves of Hippophae L, Rhizoma Chuanxiong, Hyssopus officinalis,
Rational proportion and synergistic effect between new tower flower and radix paeoniae rubra have the function of the raw new, relieving restlessness and restlessness of blood circulation and channel invigorating, stasis eliminatings, and
It is significant in efficacy, it has no toxic side effect, it is highly-safe.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all in essence of the invention
Made any modifications, equivalent replacements, and improvements etc., should all be included in the protection scope of the present invention within mind and principle.
Claims (10)
1. a kind of compound preparation for curing mainly coronary heart disease, which is characterized in that according to parts by weight, including following component:
7 ~ 19 parts of motherwort, 6 ~ 15 parts of Leaves of Hippophae L, 3 ~ 13 parts of Rhizoma Chuanxiong, 4 ~ 16 parts of Hyssopus officinalis, new tower spend 10 ~ 20 parts and radix paeoniae rubra 8 ~ 17
Part.
2. the compound preparation for the treatment of coronary heart disease as described in claim 1, which is characterized in that according to parts by weight, including it is as follows
Component:
10 ~ 19 parts of motherwort, 8 ~ 13 parts of Leaves of Hippophae L, 3 ~ 10 parts of Rhizoma Chuanxiong, 4 ~ 15 parts of Hyssopus officinalis, new tower spend 10 ~ 15 parts and radix paeoniae rubra 10 ~
17 parts.
3. curing mainly the compound preparation of coronary heart disease as described in claim 1, which is characterized in that according to parts by weight, including it is as follows
Component:
12 parts of motherwort, 12 parts of Leaves of Hippophae L, 9 parts of Rhizoma Chuanxiong, 10 parts of Hyssopus officinalis, new tower spend 12 parts and 12 parts of radix paeoniae rubra.
4. a kind of preparation method for the compound preparation for curing mainly coronary heart disease, which comprises the steps of:
Each component is weighed according to the formula of the compound preparation for curing mainly coronary heart disease as described in claim 1 ~ 3 any one, it is spare；
It is crushed after motherwort, Leaves of Hippophae L, Rhizoma Chuanxiong, Hyssopus officinalis, new tower flower and radix paeoniae rubra are separately dried, crosses 50 ~ 120 meshes, obtain
It is pulverized and mixed material；
The material that is pulverized and mixed is put into container, 4 ~ 8 times of amount water of material quantity are added, is decocted 2 ~ 2.5 hours, filtration obtains
To aqueous extract and filter residue；
Ultrafiltration is carried out to the aqueous extract, the extracting solution after obtaining ultrafiltration；
Its 5 ~ 6 times ethanol solution is added into the filter residue to carry out refluxing extraction 1 ~ 2 time, merges refluxing extraction filtrate, obtains
Alcohol extract；
By after the ultrafiltration extracting solution and alcohol extract merge, it is 1.25 ~ 1.36 that part, which is concentrated under reduced pressure into relative density,
Thick paste is concentrated；
The concentrated extract is heated to 50 ~ 65 DEG C, material 25 ~ 30 minutes, temperature is moved to and is maintained in 85 DEG C or more of drop tank；
Medical fluid is dropped in 6 ~ 8 DEG C of methyl-silicone oil, take out dripping pill, be fitted into after oil removing in capsule to get.
5. curing mainly the preparation method of the compound preparation of coronary heart disease as claimed in claim 4, which is characterized in that described by the powder
Broken mixed material is put into container, is added 4 ~ 8 times of amount water of material quantity, is decocted 2 ~ 2.5 hours, filtration, obtain aqueous extract and
The step of filter residue, comprising:
The material that is pulverized and mixed is put into container, 6 times of amount water of material quantity are added, is decocted 2.5 hours, filtration obtains water
Extracting solution and filter residue.
6. curing mainly the preparation method of the compound preparation of coronary heart disease as claimed in claim 4, which is characterized in that described to the water
The step of extracting solution carries out ultrafiltration, extracting solution after obtaining ultrafiltration, comprising:
Ultrafiltration is carried out with the filter membrane that molecule interception is 50000, filter type uses cross-flow filtration.
7. curing mainly the preparation method of the compound preparation of coronary heart disease as claimed in claim 4, which is characterized in that the behaviour of the ultrafiltration
Make condition are as follows:
Inlet pressure is 0.15 ~ 0.3MPa, and the low 0.1MPa of liquid outlet pressure ratio inlet pressure, feed velocity is 4 ~ 5m/s,
It is intermittently passed through nitrogen during ultra-filtration, forms gas-liquid stream of pulses, ventilation in every 1 ~ 1.5 hour is primary, ventilates 2 ~ 3 minutes every time.
8. curing mainly the preparation method of the compound preparation of coronary heart disease as described in claim 1, which is characterized in that described to the water
The step of extracting solution carries out ultrafiltration, extracting solution after obtaining ultrafiltration, comprising:
It keeps the temperature of the aqueous extract at 45 ~ 55 DEG C, carries out ultrafiltration, the extracting solution after obtaining ultrafiltration.
9. curing mainly the preparation method of the compound preparation of coronary heart disease as described in claim 1, which is characterized in that described to the filter
Its 5 ~ 6 times ethanol solution is added in slag to carry out refluxing extraction 1 ~ 2 time, merges refluxing extraction filtrate, obtains the step of alcohol extract
Suddenly, comprising:
Its 5 times 60% ethanol solution is added into the filter residue to carry out first refluxing extraction 1.5 hours, after filtration, is added 5
75% ethanol solution of amount carries out second refluxing extraction 2 hours again, merges the filtrate of refluxing extraction twice, obtains alcohol extracting
Liquid.
10. curing mainly the preparation method of the compound preparation of coronary heart disease as described in claim 1, which is characterized in that it is described will be described
Concentrated extract is heated to 50 ~ 65 DEG C, material 25 ~ 30 minutes, moves to the step dripped in tank that temperature is maintained at 85 DEG C or more, packet
It includes:
The concentrated extract is heated to 50 DEG C, material 30 minutes, temperature is moved to and is maintained in 85 DEG C or more of drop tank.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910906978.7A CN110522798A (en) | 2019-09-24 | 2019-09-24 | A kind of compound preparation and preparation method thereof curing mainly coronary heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910906978.7A CN110522798A (en) | 2019-09-24 | 2019-09-24 | A kind of compound preparation and preparation method thereof curing mainly coronary heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110522798A true CN110522798A (en) | 2019-12-03 |
Family
ID=68670007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910906978.7A Pending CN110522798A (en) | 2019-09-24 | 2019-09-24 | A kind of compound preparation and preparation method thereof curing mainly coronary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110522798A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111249331A (en) * | 2020-03-19 | 2020-06-09 | 新疆维吾尔医学专科学校 | Vitamin medicine composition and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1778338A (en) * | 2004-11-26 | 2006-05-31 | 天津天士力制药股份有限公司 | Chinese medicine composition for treating coronary heart disease and angina cordis |
| CN102048937A (en) * | 2009-11-05 | 2011-05-11 | 天津太平洋制药有限公司 | Chinese medicinal composition for treating and resisting platelet aggregation |
-
2019
- 2019-09-24 CN CN201910906978.7A patent/CN110522798A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1778338A (en) * | 2004-11-26 | 2006-05-31 | 天津天士力制药股份有限公司 | Chinese medicine composition for treating coronary heart disease and angina cordis |
| CN102048937A (en) * | 2009-11-05 | 2011-05-11 | 天津太平洋制药有限公司 | Chinese medicinal composition for treating and resisting platelet aggregation |
Non-Patent Citations (2)
| Title |
|---|
| 刘亚平: ""川参桃红汤治疗冠心病心绞痛60例"", 《陕西中医》 * |
| 巴哈尔古丽•黄尔汗 等主编: "《哈萨克药志 第二卷》", 31 August 2012, 中国医药科技出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111249331A (en) * | 2020-03-19 | 2020-06-09 | 新疆维吾尔医学专科学校 | Vitamin medicine composition and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103961521A (en) | Traditional Chinese medicine composition for treating aplastic anemia and preparation method | |
| CN105380051A (en) | Beverage capable of dispelling alcohol effect and protecting liver and preparation method of beverage | |
| CN101502588B (en) | Composition for beauty treatment and removing blain and method for preparing the same | |
| CN104107349A (en) | Chinese herbal medicine for three-hypers patients, and its administration method | |
| CN107233442A (en) | It is a kind of that there is the composition and fingerprint for improving gout malaise symptoms | |
| CN112336815A (en) | Anti-aging composition for strengthening body, preventing cancer and conditioning hypertension, hyperglycemia and hyperlipidemia and application thereof | |
| CN102114102A (en) | Traditional Chinese medicine extract mixed preparation and application thereof | |
| CN102302673B (en) | Traditional Chinese medicine compound preparation for preventing and treating diabetic nephropathy (DN) | |
| CN104306659B (en) | A kind of Chinese medicine composition for treating diabetes B | |
| CN104161977B (en) | It is a kind of to be used to prevent and treat Chinese medicine composition of infectious coryza of chicken and preparation method thereof | |
| CN104324310B (en) | It is a kind of to be used to treat Chinese medicine composition of fungal keratitis and preparation method thereof after immunosupress | |
| CN108210657A (en) | A kind of Chinese medicine composition for preventing and treating lung cancer | |
| CN106109521A (en) | A kind of Radix Notoginseng oral liquid | |
| CN110522798A (en) | A kind of compound preparation and preparation method thereof curing mainly coronary heart disease | |
| CN103977390B (en) | A kind of preparation method and its usage of ginger onion medicated wine composition | |
| CN103182008A (en) | Preparation method for traditional Chinese medicine used for stabilizing and reducing blood pressure | |
| CN107812115A (en) | A kind of Chinese medicine composition for treating diabetes | |
| KR20100024244A (en) | Method of manufacturing herbal chungkugjang with increased effect on lowering the blood glucose content | |
| CN103933216B (en) | A kind of compound blood pressure reducing capsule for treating metabolic high blood pressure and its preparation and application | |
| CN113499425A (en) | Composition for treating viral influenza and preparation method thereof | |
| CN103099885A (en) | Soft capsules having acne removing function and preparation method thereof | |
| CN104606570A (en) | Consumptive thirst tea substitute drink suitable for diabetes patients and preparation method of consumptive thirst tea substitute drink | |
| CN103784736A (en) | Medicine composition for treating pregnancy toxaemia of equus animals | |
| CN104547259B (en) | A kind of Traditional Chinese medicine for decreasing blood sugar acetum | |
| CN101574427B (en) | Traditional Chinese medicine compound for aiding drug rehabilitation and traditional Chinese medicine containing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191203 |